Is there a recipe for M&A success? The best and worst buyout deals in the past decade offer some keys to success — and failure
It’s not easy achieving a solid win in M&A in this industry. But if you follow a few simple guidelines, you may be able to increase your odds of success.
Geoffrey Porges and the team at SVB Leerink went about the “notoriously difficult” task of scoring the biopharma buyout of 2009 to 2019. Sizing up current and expected revenue from the products that were gained, they came up with the 5 winners:
It says a lot about the field that it’s much easier sorting out the 5 worst deals, though there’s also a lot more competition for that title, notes Porges. As picked by the analysts:
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 64,900+ biopharma pros reading Endpoints daily — and it's free.